RTP Mobile Logo
Select Publications

Armstrong AJ et al. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. Genitourinary Cancers Symposium 2019;Abstract 687.

Chi KN et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): An international, randomised phase 3 trial. Lancet Oncol 2018;19(2):194-206. Abstract.

De Bono JS et al. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Proc ESMO 2019;Abstract 847PD.

De Giorgi U et al. A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy. Genitourinary Cancers Symposium 2019;Abstract 185.

De Wit R et al; CARD Investigators. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019;381(26):2506-18. Abstract

Fizazi K et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20(5):686-700. Abstract

Fizazi K et al; ARAMIS Investigators. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235-46. Abstract

Gravis G et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: Further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol 2018;73(6):847-55. Abstract

Hussain M et al. PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. Proc ESMO 2019;Abstract LBA12_PR.

Hussain M et al. Enzalutamide in castration-resistant prostate cancer. N Engl J Med 2018;379(14):1381. Abstract

Hussain M et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018;378(26):2465-74. Abstract

Hussain M et al. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results from NCI 9012. J Clin Oncol 2018;36(10):991-9. Abstract

Kyriakopoulos CE et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36(11):1080-7. Abstract

Marshall CH et al. Response to PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with BRCA1/2 versus ATM mutations. Genitourinary Cancers Symposium 2019;Abstract 154.

Parker C et al; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-23. Abstract

Sartor AO et al. A retrospective analysis of treatment patterns in metastatic castration-resistant prostate cancer patients treated with radium-223. Genitourinary Cancers Symposium 2019;Abstract 180.

Small EJ et al. Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC). Genitourinary Cancers Symposium 2019;Abstract 144.

Smith M et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(3):408-19. Abstract

Smith MR et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD. Genitourinary Cancers Symposium 2019;Abstract 202.

Smith MR et al; SPARTAN Investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018;378(15):1408-18. Abstract

Tombal B et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20(4):556-69. Abstract

VanderWeele DJ et al. Metastatic hormone-sensitive prostate cancer: Clinial decision making in a rapidly evolving landscape of life-prolonging therapy. J Clin Oncol 2019;37(32): 2961-7. No abstract available